PEC-Direct
PEC-Direct is being developed for patients with type 1 diabetes who are at the highest risk of life-threatening acute complications.
Read MoreRegenerating Health
ViaCyte is a regenerative medicine company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for all type 1 diabetes and a next-generation treatment for insulin-requiring type 2 diabetes.
ViaCyte is committed to delivering transformative cell replacement therapies for insulin-requiring diabetes.
The PEC-Direct and PEC-Encap product candidates are in clinical trials for type 1 diabetes.
ViaCyte’s pluripotent stem cell-based technologies are designed to address the limitations of donor islet transplants and represent a major advance in the development of a functional cure for type 1 diabetes. ViaCyte’s implantable medical devices are designed to contain our cell replacement therapies and allow for cell survival and function. Together, these technologies have the potential to create leading cell replacement therapies designed to functionally cure human diseases.
ViaCyte has continually broken new ground in medical device engineering, stem cell research, and cell therapy scaling and manufacturing.
To have our press releases and major updates sent to you, please provide your name and email address.
Type on the line above then press the Enter/Return key to submit a new search query